Burnham Institute for Medical Research and Magellan BioScience Group, Inc. Announce Drug Discovery Col...( Magellan Bio...)

Magellan BioScience Group, Inc. (Magellan), a pioneer in innovative drug development from marine sources, and investigators at the Burnham Institute for Medical Research at Lake Nona (Burnham) announced today that they will begin a multidisciplinary drug discovery collaboration to identify novel marine microbial compounds that have potential as tools for biological research and ultimately the discovery of new medicines.

Tampa and Orlando, FL (Vocus) July 7, 2009 -- Magellan BioScience Group, Inc. (Magellan), a pioneer in innovative drug development from marine sources, and investigators at the Burnham Institute for Medical Research at Lake Nona (Burnham) announced today that they will begin a multidisciplinary drug discovery collaboration to identify novel marine microbial compounds that have potential as tools for biological research and ultimately the discovery of new medicines.

This collaboration will bring together Magellan’s unique collection of marine-derived microorganisms and their natural product chemistry expertise with Burnham’s ultra-high throughput small molecule screening technologies that were recently established at the Lake Nona, Florida campus. The Burnham-Magellan team will utilize Burnham’s state-of-the-art robotic screening system to run bioassays and characterize lead candidates from the collection. The Burnham team of Medicinal Chemists will then optimize novel compounds to afford potential biological probes and preclinical drug candidates. The groups’ combined expertise in sophisticated chemistry approaches and access to advanced screening technologies, will accelerate early discovery and drug development efforts.

“We are excited to initiate this discovery collaboration with Burnham,” said Dr. Todd R. Daviau, CEO of Magellan. “Burnham’s scientific and technological approach coupled with their highly-qualif
'/>"/>